Introduction
Malignant gliomas present a tremendous therapeutic challenge in spite of advances in accepted treatment modalities such as surgery, radiotherapy and chemotherapy. Survival of patients from the time of diagnosis is measured in months and recurrence after treatment is associated with a life expectancy of weeks. Among the therapies being attempted are destruction of tumor cells by genetically engineered viruses and immunotherapy.
Elsewhere, we and others have described the use of genetically engineered herpes simplex virus (HSV) for treatment of malignant gliomas. [1] [2] [3] In the course of these studies it became apparent that the 'cures' observed in the course of treatment of immunocompromised or immunocompetent mice could not be ascribed entirely to the destruction of all tumor cells by the virus. A central question therefore was whether infection induced an immune-related inflammatory response to the tumor cells and whether the response could be modified by cytokines expressed from genes cloned into the virus.
Enhancement of the immune response to malignant gliomas has recently emerged as a major avenue of potential therapy. This approach is based on the observation that patients with malignant brain tumors are immunosuppressed, specifically for their T cell functions. 4 Gliomas are poor antigen presenting cells in vivo with low expression of MHC class I and II antigens. 5 They also secrete several immunosuppressive molecules such as TGF-␤2 and prostaglandin E 2 . 6 Thus, a major goal of immunotherapy is to stimulate recognition of tumor cells by the host's immune system and to activate tumor antigen-specific cellular immunity. Some of the methods that are currently under investigation as immunotherapy for malignant gliomas include active immunization with tumor-specific antigens and adoptive immunotherapy. 7 Direct transfer of cytokine genes in tumor cells has emerged as a powerful immunotherapeutic tool in the new approaches for the management of cancer patients. In experiments with animal models, tumor cells transduced with cytokines and growth factor genes such as 122 interleukin IL-1, 8 IL-2, 9 IL-4, 10,11 IL-6, 12,13 IL-7, 14, 15 interferon (IFN-␥), 16, 17 tumor necrosis factor (TNF)-␣, 18, 19 granulocyte-macrophage colony-stimulating factor (GM-CSF), 20, 21 have demonstrated in vivo inhibition of tumor growth by stimulating localized inflammatory and/or immune responses. In contrast, cytokines such as IL-5 22 and IL-10 23 demonstrate lack of localized tumor killing and generation of host immunity, and TGF-␤2 24 causes inhibition of tumor immunogenicity.
The therapeutic efficacy of cytokine gene therapy in intracerebral tumors has been attempted only recently. Retrovirus vectors are utilized primarily to transduce glioma cells with cytokine genes. [25] [26] [27] [28] Other vectors such as adenovirus and herpes simplex virus that can express the foreign gene extrachromosomally and/or that can replicate conditionally within the tumor might produce a more potent cytokine-mediated antitumor effect.
The experimental design we tested was based on the following considerations. If the cytolytic effects of HSV were the sole cause of tumor destruction, neither IL-4 nor IL-10 would exert an effect on the survival of tumorbearing mice. If the tumor destruction induced by HSV could be enhanced by an immune response to the tumor cells, we could expect that intratumoral generation of IL-4 would produce a prolongation in median survival time whereas IL-10 production would diminish median survival time to that of saline or untreated animals. The results of our studies indicated that the hypothesis was tenable: (1) survival of glioma-bearing mice treated with the recombinant virus expressing the IL-10 gene was reduced to that of glioma-bearing mice mock-treated with saline; and (2) survival of mice treated with the IL-4-expressing virus was significantly prolonged.
Results

Construction of recombinant HSV-expressing murine IL-4 or IL-10
The first objective of these experiments was to construct two recombinant viruses in which both copies of the ␥ 1 34.5 gene in the wild-type HSV-1(F) were replaced by cDNAs encoding specific cytokines. The cDNAs of the inserted cytokines encode 140 codons for IL-4, and 178 codons for IL-10. For these studies the Egr-1 promoter was chosen to enable maximal expression of the inserted gene in dividing cells. The construction of the recombinant viruses was done in two steps. In the first step, approximately 700 bp of the ␥ 1 34.5 genes were replaced by a chimeric gene consisting of the coding domain of the HSV-1 (F) tk gene fused to the promoter of the ␣27 gene to yield a recombinant virus R3659 described elsewhere. 29 In the second step, both copies of the ␣27-tk genes were replaced by the chimeric genes encoding the cytokines. The native tk site was then repaired. Figure 1 provides a schematic illustration of the structure of these wild-type and recombinant viruses. The structure of the recombinant viruses was verified by hybridization of specific 32 P-labeled probe DNAs to electrophoretically separated digests of recombinant virus DNAs (data not shown). Although the two recombinant viruses, R8306 (IL-4) and R8308 (IL-10) were constructed to resemble R3616, which lacks both copies of the ␥ 1 34.5 gene, they replicated better than R3616 in the HFF cultures. In fact, in all assays, R3616 grew poorly while R8306 and R8308 recombinant viruses grew almost as well as the wildtype virus.
Growth of wild-type and recombinant viruses in tumor cell lines Replication studies of recombinant viruses in U251MG and D54MG human glioma cells are shown in Figure 3 . In the U251MG cells, peak titers were obtained 24 h after infection although high titers persisted for at least another 48 h. The R8306 and R8308 recombinant viruses replicated to a level close to that of the wild-type virus whereas R3616 replicated to significantly lower levels. In D54MG glioma cells, peak titers were obtained 48 h after infection although almost identical virus titers were observed at 24 and 72 h after infection. R8306 and R8308 recombinant viruses grew to titers which were at most 10-fold lower than those of the wild-type virus whereas the titers of R3616 were significantly lower. 
Production of cytokines by recombinant HSV-infected cells
Replicate cultures of Vero cells were either mock-infected or infected at 1.0 p.f.u. of recombinant virus per cell. Extracellular media were collected at 48 h after infection, clarified by centrifugation and the levels of cytokines were determined semiquantitatively by ELISA as described in the Materials and methods. As shown in Table 2 , the interleukin-carrying recombinant viruses induced the production of cytokines to levels ranging from 1300 to 1900-fold higher than the background amounts measured in the mock-infected cells. The background levels detected represent the lower limit of sensitivity of the respective ELISAs. As expected, cells infected with R3616 also produced only background levels of the measured cytokines (data not shown).
Survival of C57BL/6 mice with intracerebral GL-261 gliomas A dose-response study was conducted to determine the relation between the number of GL-261 glioma cells injected intracerebrally and host survival. Injection of 10 mice receiving the highest dose had a median survival of 17 days, and those receiving progressively fewer tumor cells (10 4 or 10 3 ) survived correspondingly longer (30 and 38 days median survival, respectively). These survival differences were statistically significant when the later values were compared with those of mice receiving the highest inoculum (P Ͻ 0.01 and P Ͻ 0.0001, respectively). For the purposes of these glioma model studies, we selected the 10 5 dose of GL-261 cells since this produced a median survival of 17-19 days which was reproducible and would provide a rapid answer regarding the capacity of these recombinant viruses to exert an antitumor effect and prolong survival.
To establish the sensitivity of these tumor cells for the direct cytolytic effects of viruses lacking the ␥ 1 34.5 gene, GL-261 gliomas were induced in C57BL/6 mice. After 5 days, mice were randomized into groups of 10 animals and given an intratumoral injection of either 10 6 p.f.u. of R3616 or R4009 HSV or sterile excipient used to suspend the viruses (5 l total volume). Mice receiving R3616 HSV had a median survival of 19 days, which was not statistically significant (P = 0.10, log-rank) from the median survival of mice receiving sterile excipient solution ( Figure  5 ). On the other hand, mice receiving R4009 had a median survival of 27 days, which was statistically longer (P = 0.0020) than 'excipient'-treated mice. This difference was similar to that previously reported for these two mutants using a different glioma model, MT539MG mouse glioma cells implanted, then treated intracerebrally in scid mice. 2, 3 GL-261 glioma cells were implanted intracerebrally in C57BL/6 mice and 5 days later, tumor-bearing mice were injected with 5 × 10 6 p.f.u. of R8306 or R8308 viruses or with sterile excipient solution through the same burr hole to the same stereotactic coordinates used to implant the tumor cells. Survival of mice in each group was monitored and results are shown in Figure 6 . Mice receiving saline experienced a predictable median survival of 18 days, while mice receiving a single dose of R8306 (IL-4) had a median survival of 24 days. This difference was statistically significant (P = 0.0016, log-rank) and was reproducible in four separate experiments. In contrast, the median survival of mice that received R8308 (IL-10) was not different from that of the mice receiving sterile excipient solution (18 days; P = 0.8585). The inability of R8308 to modulate the survival of GL-261-bearing C57BL/6 mice was also a reproducible finding in three separate experiments.
We next employed different doses of R8306 to determine the capacity of this virus to produce a statistically significant increase in survival. In Figure 7 , GL-261-bearing mice received either 2 × 10 5 or 2 × 10 6 p.f.u. of R8306 or sterile excipient solution 5 days after tumor cell implantation. Compared with the excipient solutiontreated mice, the higher dose produced a significant increase in survival (P = 0.0068; Peto-Wilcoxon) while the lower dose did not (P = 0.2554).
Finally, we attempted to isolate recombinant viruses from treated mice at the time they were killed due to advancing morbidity but these attempts yielded no active virus.
Infiltration of immune-related inflammatory cells in GL-261 gliomas
In one of the series of survival experiments, we included in each group additional mice to be killed at 3 and 7 days after therapy for immunohistochemical analyses. GL-261 gliomas were induced in C57BL/6 mice and 5 days later, groups of six mice received either sterile excipient solution (5 l) or 2 × 10 6 p.f.u. of R3616, R8306 or R8308. In addition, a group of naïve mice were operated on and a sterile injection needle inserted through the burr hole, withdrawn and reinserted without injection. These nontumor-bearing mice were designated as 'stab-wounded'. Three days later, three mice were chosen at random from each group, killed, the brains removed, sectioned freehand coronally through the injection site and mounted in OCT medium. Serial frozen sections were stained with monoclonal rat antibodies to identify T cells (CD4 + or CD8 + ), B lymphocytes (anti-IgD) or macrophages/ microglia. Microscopic inspection of these sections revealed that the most prevalent intratumoral immunerelated cell type was the macrophage. Macrophages were the most obvious cell type 3 days after virus injection (8 days after tumor induction) and increased markedly by 7 days after treatment ( Figure 8 , right column; 12 days after tumor). There seemed to be little difference in the proportions of macrophages in these tumors regardless of treatment. The numbers of macrophages counted within 3 to 5 high power (400×) microscopic views of identifiable tumors in the brains of these mice ranged from 19 ± 5 per 400× field for the R3616 HSV to 22 ± 4.3 per 400× field for tumors treated with R8306. The same lack of significant differences for CD4
+ cells was also noted, ranging from 21 ± 4.8 per 400× field for tumors treated with R8306 to 15 ± 7.3 per 400× field for R8308-treated tumors. However, it was noted that the numbers of CD8
+ cells were decreased in tumors of mice treated with R8308 (IL-10) (Figure 8 In addition, we also stained adjacent sections with antibody to HSV which revealed an occasional positively stained cell at day 3 but an absence of any positively stained cells by day 7 after treatment (data not shown).
Sections of tissues (spleen, liver and kidney) from these same mice were used as positive controls for the antileukocyte antibodies. No discernible differences were noted in the distribution or staining patterns of these tissues as a result of recombinant virus injection into the brains of these mice (not shown). These tissues were also negative for HSV by antibody staining (not shown).
Plasma cytokine levels
Plasma cytokine levels were detected following inoculation in GL-261 cells alone with saline treatment (control) days 7 and 15 and consisted of IL-4 and IL-5 early and IL-4 and IFN␥ at the late time-point. For mice treated with IL-4 or IL-10 mutant, plasma levels were virtually identical to those following GL-261 cells alone.
Discussion
The treatment of human malignant gliomas remains a formidable problem in as much as therapeutic advances have not significantly improved clinical outcome. The utilization of viruses has become one of the current therapeutic modalities under intensive study as possible therapeutic agents in humans. Our current studies have been built upon our previous observations which recognize that genetically engineered HSV with deletion or stopcodon mutations in the ␥ 1 34.5 gene significantly prolonged survival, and in some instances 'cured' scid mice implanted intracerebrally with human glioma cells. 3 A central problem in the treatment of malignant gliomas with oncolytic viruses rests on the fact that it is unlikely that all tumor cells can be infected and destroyed by a single or even multiple administrations of the virus. Hence oncolytic viruses must rely on other factors such as the host immune response, in addition to the cytotoxic effects resulting from viral gene expression. The experiments described in this report were designed to determine whether the host immune response played a role in the prolonged survival of immune-competent mice carrying implants of mouse gliomas and treated with HSV recombinant viruses.
The salient features of our results were as follows: (1) As in the scid mice implanted with either murine or human glioma cells, the C57BL/6 mouse proved suitable for intracranial induction of tumors that were uniformly fatal. An inoculum of 10 5 tumor cells yielded reproducible tumor development with a median mortality in a reasonable period of time to permit post-tumor induction therapies, ie slightly longer than 2 weeks. (2) Genetically engineered HSV recombinants efficiently replicated in human foreskin fibroblasts, human glioma cells and Vero cells and expressed the cytokine genes inserted into the viral genomes. (3) Survival of glioma-bearing mice treated with recombinant viruses varied depending on the cytokine gene inserted into the virus. These studies provide the first evidence that host immunity to glioma cells played a role in the oncolytic effects achieved by viral treatment of tumors with replication competent, attenuated cytotoxic viruses.
Finally, these data provide preliminary evidence that regulation of the immune response, indeed, does contribute to survival. In these studies, the IL-4 mutant prolonged survival and was associated with striking infiltration of the tumor by macrophages, CD4
+ and CD8 + T cells. In contrast, IL-10, which down-regulates the immune response, led to survival no different than seen with R3616 or saline-treated controls. The histopathology was also somewhat different in that there was a virtual absence of CD8 + T cells and B cells (not shown) 7 days after injection of this mutant. Of interest, there was no evidence either by clinical appearance or by histological examination that these recombinant viruses produced a toxicity in the brain other than that which could be attributed to the tumor. This is entirely consistent with the previous report that ␥ 1 34.5 − HSV fail to replicate in normal brain cells in immunocompetent mice. 30 The test system consisted of immunocompetent C57BL/6 mice with intracranial gliomas induced with syngeneic GL-261 cells in a manner similar to our previous studies. The definition of the quantity of cells required for a stringent model in immunologically intact hosts was an essential first step. We note that comparison of median survivals between different tumor models (eg syngeneic versus xenogeneic) is not possible because of the significantly different phenotypic properties of these cells and resulting tumors upon CNS inoculation, as well as the nature of the hosts (immunocompromised scids versus immunocompetent C57BL/6). Further, the GL-261 glioma cells appear to be among the most aggressive of all tumor models with which we have worked; thus, we did not expect to observe any 'cures' or long-term survivors from these studies. As will be discussed later, this is an important consideration in comparison with immune stimulation seen in other experimental glioma model systems.
The second component of the test system consisted of a ␥ 1 34.5
− recombinant virus-carrying cytokine genes. As we have previously reported ␥ 1 34.5 − HSV can replicate well in HFF, Vero cells and human glioma cells. 2, 3, 29, 31 For reasons that are not clear, replication in HFF was more variable than we would have expected and may be attributable to the cytokine gene products or to other undetermined factors. Regardless, replication of the cytokine-expressing HSV in tumor cell lines was relatively homogeneous and comparable to wild-type HSV-1(F). In all instances, replication of R3616 in all cells was substantially lower than the cytokine-expressing HSV. Cytokines were selected for two reasons. First, because they have predictable effects on the immune response, and second, because they have been used in experimental tumor treatment in other systems. Cytokine gene therapy is currently used as a strategy to induce antitumor effects in various model systems and indeed, both retrovirus and adenovirus vectors have been used to transduce tumor cells and treat experimental animal tumors. While a variety of cytokines were available for this initial investigation, we chose for these studies Il-4 and IL-10. The selection of IL-4 was predicated upon its known ability to induce macrophage and CD8 T cell proliferation, as well as B lymphocyte differentiation. IL-4 is also one of the few interleukins whose interaction with its receptors is species-specific. To contrast with this potential for enhancement of the immune response, we selected IL-10 due to its known capacity to suppress host immune responses. 32 As noted in the Introduction, the expectation was that if the cytokines were not expressed or if the immune system played little or no role in tumor progression, the median survival of tumor-bearing mice treated with cytokine-expressing virus would be similar to that of mice treated with noncytokine expressing virus.
Clearly, other vector systems have been used in other rodent glioma model systems to transduce genes for immune-stimulating cytokines. Wei et al 28 described two methods for IL-4 treatment of rat C6 glioma cells implanted subcutaneously or intracranially in nude mice. Rat C6 cells were comixed with one of two different mouse fibroblast cell lines producing mouse IL-4 only or IL-4 plus an IL-4-encoding retrovirus. Median survival was greater with the retrovirus-producing fibroblast cells. Challenge of rat C6 gliomas that had been established intracranially 3 days previously in nude mice was similarly successful in prolonging median survival although all mice eventually died. Interestingly, these authors reported a significant and long-lasting eosinophil infiltration. In our studies in a syngeneic immunocompetent mouse system, eosinophils were not a significant identifiable component of the inflammatory response. We can only speculate that in the absence of a significant T cell population in nude mice, perhaps it is not surprising that the principal inflammatory response would be eosinophils and macrophages.
How important is the choice of a rodent glioma model in assessing the role of the immune response in the poorly understood phenomenon of tumor regression? There probably is no single model that will be predictive, but there are several models in which tumor regression is more easily demonstrated. The 9L gliosarcoma model in Fischer 344 rats appears to be one of the latter. This cell line was reported over 20 years ago to be highly immunogenic in syngeneic F344 rats 33 and several types of gene therapy maneuvers have been reported to induce tumor regression and long-lasting immunity. [34] [35] [36] The latter paper is most relevant to our studies in that a replication-defective but thymidine kinase positive HSV was demonstrated to produce 'cures' following gancyclovir therapy. 36 We were not able to demonstrate cures in our mouse glioma model and this may be attributable to the fact that the GL-261 glioma is a highly aggressive tumoras few as 1000 glioma cells implanted intracranially produced 100% uniform lethality in its syngeneic hosts. We have not yet established the immunogenicity of the GL-261 mouse glioma cell line but unlike the 9L studies, HSV-mediated gene therapy was only palliative, not curative, and we had no survivors to test the development of a protective immunity.
To our knowledge, these studies are also the first example of the use of HSV both as a cytotoxic agent and as a vector of nonviral genes that can enhance tumor destruction. They open the possibility of using other genes which alter the nature of the immune response. The cells were propagated in Dulbecco's modified Eagle's medium supplemented with 5% fetal bovine serum. HSV-1(F) is a low passage clinical isolate used as the prototype HSV-1 strain in our studies. 37, 38 R3616 was derived by deletion of 1000 bp from the coding domain of the ␥ 1 34.5 genes in HSV-1(F). 29 In recombinant R4009, a sequence encoding the stop codon in all six reading frames was inserted into the coding domains of the ␥ 1 34.5 gene. Experiments described elsewhere in detail suggest that the stop codon in the ␥ 1 34.5 genes is suppressed at a very low level 29 and this may account for the greater efficacy of R4009 in destroying tumor cells. 2, 3 The stocks of recombinant viruses used in these studies in vivo and for assays of virus growth in tumor cell lines were prepared in human foreskin fibroblast (HFF) cultures.
Materials and methods
Cells and viruses
Mouse glioma-261 (GL-261) tumor was purchased from the Division of Cancer Treatment Tumor Repository, Frederick, MD, USA, as cryopreserved tumor fragments at an unknown passage in C57BL/6 mice from the original isolate. 39 Tumor induction was performed by Dr MJ Shear by intracerebral implantation of 20-methylcholanthrene pellets as was originally described for C3H strain mice. 40 Because the GL-261 mouse glioma was originally passaged by subcutaneous trochar in C57BL/6 mice, it was lactate dehydrogenase (LDH) virus positive, due to infection of passenger macrophages. To remove LDH virus-infected macrophages, we established the tumor cells in culture as follows. Fragments were thawed, trypsinized and seeded into tissue culture flasks in DMEM/F12 culture medium described below. Cells that grew out were passaged by trypsinization and after 12 passages the cells were determined to be LDH virusnegative, characterized as glial fibrillary acidic protein (GFAP) positive with typical glial intermediate filaments and grew well after intracerebral inoculation in mouse brain. 41 Human glioma cell lines U251MG and D54MG were obtained from DD Bigner (Duke University, Durham, NC, USA). Tumor cells were maintained in Dulbecco's modified Eagle's medium mixed 1:1 with Ham's nutrient mixture F-12 (DMEM/F12), supplemented with 2 mm lglutamine and 7% fetal bovine serum (FBS). Vero cells (ATCC) were utilized to grow the parental virus, HSV-1(F), or recombinant viruses in minimal essential medium (MEM) supplemented with 10% heat-inactivated FBS and gentamicin (50 g/ml).
Plasmids
The plasmids containing murine cytokines were obtained from the ATCC. Plasmid p2A-E3 contains a 0.59 kbp BamHI fragment of murine IL-4 cDNA cloned into the BamHI site of pBR322. Plasmid pcD(SR␣)-F115 contained a 1.34 kbp fragment encoding murine IL-10 cDNA cloned into the BamHI site of pcDSR␣. PRB4874 contains a 0.48 kbp XbaI-SalI fragment of the Egr-1 promoter sequences. PRB4875 contains the BamHI S fragment of HSV-1(F) cloned into the BamHI site of pUC9. PRB3879 contained a 0.58 kbp DNA fragment encoding the hepatitis B virus polyA signal sequences.
To construct a cytokine-expressing cassette, pRB4875 was cleaved with BstEII and BspEI, and a 0.77 kbp fragment containing most of the ␥ 1 34.5 gene coding sequences was replaced with the double stranded DNA oligomer linker (GTAACCCTCGAGGGTACCAGATCT-GTCGACGATATCTCTAGAT and its complement, CC GGATCTAGAGATATCGTCGACAGATCTGGTACCCT CGAGG) to yield pRB4876. pRB4876 was then digested with XhoI and treated with Klenow fragment to blunt the ends of the DNA fragments. A 0.48 kbp SphI-KpnI fragment containing the Egr-1 promoter from pRB4874 was blunted with T4 polymerase and ligated in the XhoI/Klenow site of pRB4876, yielding plasmid pRB4877. PRB4877 was digested with EcoRV, and a 0.58 kbp KpnI fragment containing hepatitis B polyA signal sequence from pRB3879 was blunted with T4 polymerase and then inserted into the EcoRV site of pRB4877, resulting in plasmid pRB4878 that consists of the Egr-1 promoter, polylinker sites and the hepatitis B polyadenylation signal.
To construct the cytokine expressing plasmid pRB4879, pRB4878 was cleaved with KpnI and blunted with T4 polymerase, then a 0.95 kbp BamHI-HindII/Klenow fragment containing IL-10 cDNA from pcD(SR␣)-F115 was inserted into the KpnI/T4 polymerase site of pRB4878. In this plasmid, the expression of IL-10 was driven by the Egr-1 promoter. PRB4881 was constructed by ligating a 0.59 kbp BamHI/Klenow fragment that contained IL-4 cDNA from p2A-E3 into the KpnI/T4 polymerase site of pRB4878.
Construction of recombinant viruses
Transfection of viral DNA was done in rabbit skin cells by a method previously described, 37 the selection for tk+ viruses was performed on 143TK
− cells overlaid in HAT medium (Dulbecco's MEM containing 5% FBS, hypoxanthine, aminopterin and thymidine), whereas the selection of tk− viruses was done on 143TK
− cells overlaid with DMEM containing 5% newborn calf serum and 100 g of bromodeoxyuridine (BUdR) per milliliter of medium. Viral DNAs were isolated from infected cells and purified on NaI gradients. 42 The recombinant viruses R8305 and R8307 were obtained by cotransfection of R3659 43 viral DNA with either plasmid pRB4881 or pRB4879 and by selecting tk− progeny viruses in 143TK
− cells overlaid with medium containing BUdR. Recombinant viruses R8306 and R8308 were constructed by cotransfection of rabbit skin cells with plasmid pRB4867 and R8305 or R8307 viral DNA, respectively. tk+ Viruses corresponding to R8306 and R8308 were selected by plating the progeny of transfection on 143TK
− cells in HAT medium. The genotype of recombinant viruses selected in this fashion was verified by hybridization of electrophoretically separated restriction enzyme digests with appropriate 32 Plabeled DNA probes as previously described. 44 Quantification of cytokines produced Cytokines were quantified by ELISA. 45 Falcon Microtest II plates (Becton Dickinson, San Jose, CA, USA) were coated with 100 l of anti-cytokine antibody diluted in PBS and incubated overnight at 4°C. Anti-cytokine antibodies used were BVD4-1D11, 2.0 g/ml (IL-4) and JES5-2A5, 2.0 g/ml (IL-10) which were obtained from Pharmingen, San Diego, CA, USA. The wells were blocked with PBS-T (phosphate buffered saline-Tween) containing 1% BSA (bovine serum albumin) at room temperature for 1 h. Serial two-fold dilutions of supernatants were added to duplicate wells and incubated overnight at 4°C. The wells were washed with PBS-T and incubated with appropriate biotinylated anticytokine mAB (monoclonal antibody) diluted in PBS-T with 1% BSA for 1-2 h. The following biotin-rat antimouse (Pharmingen) were used: BVD4-24G2, 0.2 g/ml (IL-4) and SXC-1, 0.3 g/ml (IL-10). After thorough washing, wells were incubated with peroxidase-labeled antibiotin antibody (0.5 g/ml; Vector Laboratories, Burlingame, CA, USA) for 1 h and developed with ABTS containing H 2 O 2 (Moss, Pasadena, MD, USA). Standard curves were generated using murine rIL-2 (Pharmingen), rIL-4 (Endogen, Boston, MA, USA), rIL-5 and rIL-10 (Genzyme, Cambridge, MA, USA). Background was determined for each cytokine assay by substituting different recombinant cytokines as the only change.
Serial blood samples (approximately 200 l) were taken from the retro-orbital sinus of anesthetized mice for determination of plasma cytokine levels as described above.
Replication competence of HSV constructs
Replication competence was determined in normal and tumor cell lines. The ability of the engineered HSV recombinants to replicate in Vero and human foreskin fibroblasts was determined using either 0.1 or 1.0 p.f.u. per cell. Dividing and contact-inhibited cultures of Vero and human foreskin fibroblasts were generated as follows. Two sets of trypsinized cells were plated in 24-well tissue culture trays (Becton Dickinson). One set of cells was infected with the recombinant viruses or HSV-1(F) 24 h after seeding. The second set was incubated for 3 days in medium containing 7% FBS and subsequently transferred into medium with 2% serum for an additional 129 2 days to generate contact inhibited monolayers before infecting.
For tumor cell lines, murine GL-261 and human glioma cell lines, U251MG and D54MG were seeded at subconfluent densities and infected with 1 p.f.u. per cell with R8306, R8308, or R3616. HSV-1(F) was used as the wildtype control. After adsorption (1 h, 37°C), monolayers were washed, overlaid with medium and further incubated (37°C, 5% CO 2 ). Cell monolayers were harvested at 4, 12, 24, 48 and 72 h after infection, sonicated and lysates assayed for their ability to form plaques on Vero cell monolayers. Vero cells were fixed and stained with MayGrü nwald (Aldrich, Milwaukee, WI, USA) and Giemsa (Sigma Diagnostics, St Louis, MO, USA) stains and plaques were counted by light microscopy.
Intracranial tumor implantation
To determine whether HSV-expressing cytokines would have antitumor effect, an intracranial tumor model was developed with syngeneic murine GL-261 glioma cells in immunocompetent C57BL/6 mice. A dose-response survival curve was established using graded doses of GL-261 cells injected into the right caudate nucleus of C57BL/6 mice. Briefly, GL-261 cells were harvested from tissue culture, washed in serum-free DMEM/F12, counted in trypan blue dye to identify live cells, and diluted in an equal volume of 10% methyl cellulose to achieve doses of 10 3 , 10 4 and 10 5 cells per 5 l. A 5-l aliquot was inoculated in the right caudate nucleus as described previously. 3 Delayed therapy experiments were undertaken and animals were randomized in groups of 10. In a typical experiment, 10 5 GL-261 cells were implanted in the right cerebral hemisphere, allowed to divide for 5 days before graded doses of different viruses were injected intratumorally in a volume of 5 l. In parallel control groups, 10 mice received saline solution in place of virus. All tumor-bearing C57BL/6 mice were followed for survival in order to establish Kaplan-Meier survival plots, as previously reported. 2, 3 Parallel groups of tumorbearing mice treated similarly were randomly assigned to survival intervals of 3 and 7 days after virus therapy, when their brains were harvested and further analyzed by immunohistochemical analysis.
As mice became moribund from progressive tumor growth, they were killed and their survival time taken as the date of death. Animal studies were conducted in accordance with guidelines for animal use and care established by The University of Alabama at Birmingham Animal Resource Program and the Institutional Animal Care and Use Committee.
Virus recovery from CNS Attempts to isolate HSV recombinants from the brain tissue of dead mice were performed as previously described.
2,3,31
Immunohistochemistry Virus-treated and saline-treated C57BL/6 mice were killed at 3-and 7-day intervals and brains were frozen in Tissue-Tek OCT compound (Miles, Kankakee, IL, USA). In a separate group of mice, instead of implanting intracranial tumor, defined stab wounds were generated in the same place with a needle to provide a control group for mechanical trauma produced by intracerebral injection. Serial sections were cut at 10-12 m intervals and mounted on TEPSA-coated slides, fixed in 95% ethanol, and blocked in PBS-2% BSA. Endogenous peroxidase activity was blocked by incubation for 30 min at room temperature with 0.3% H 2 O 2 in methanol. Immunoperoxidase staining was performed using the avidin-biotin complex peroxidase Vectastain ABC kit (Vector Laboratories, Burlingame, CA, USA). Slides were incubated with primary antibodies for 30 min at room temperature. Monoclonal antibodies (Tissue Core; UAB, Birmingham, AL, USA) for inflammatory cells used were GK1.5 (CD4), Lyt2 (CD8), JA12.5 (IgD) and F4/80 (macrophage). Herpes simplex virus (HSV) was detected with a rabbit polyclonal antibody to HSV thymidine kinase (William Summers, Yale University, New Haven, CT, USA). After washing thoroughly, sections were incubated with appropriate biotin-labeled secondary antibodies (Vector Laboratories) for 30 min at room temperature. Color reaction was carried out using 3,3′-diaminobenzidine according to the manufacturer's instructions. Tissue sections were counterstained with Mayer's hematoxylin and permanently mounted with permount. Sections of spleen, liver and kidney from the same animal served as the negative control. Positively staining immune-related inflammatory cells in 3-5 high power fields (× 400) that included tumor cells were counted and averages determined for each cell type.
